IL6 and coronary artery disorder: The lately reported Cardiovascular Inflammation Reduction Trial (CIRT) failed to reduce cardiovascular events as well as levels of interleukin-1β, interleukin-6 and C-reactive protein with low-dose methotrexate, underling the crucial role of targeting the interleukin-1β pathway in the treatment of CHD [38].